China Pharma Holdings Stock Probability Of Bankruptcy

CPHI Stock  USD 0.20  0.01  5.26%   
China Pharma's odds of distress is over 60% at the present time. It has an above-average probability of going through some form of financial crisis in the next 2 years. Probability of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the China balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out China Pharma Piotroski F Score and China Pharma Altman Z Score analysis.
  
The current Market Cap is estimated to decrease to about 2.2 M. Enterprise Value is estimated to decrease to about 5.7 M

China Pharma Holdings Company probability of distress Analysis

China Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current China Pharma Probability Of Bankruptcy

    
  Over 60%  
Most of China Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China Pharma Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of China Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting China Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of China Pharma Holdings financial health.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.69)
Revenue Per Share
0.63
Quarterly Revenue Growth
(0.16)
Return On Assets
(0.18)
Return On Equity
(0.75)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

China Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for China Pharma is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since China Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China Pharma's interrelated accounts and indicators.
1.00.180.970.80.890.620.930.120.280.930.380.320.750.190.51-0.45-0.090.50.420.720.650.13
1.00.090.980.790.920.550.950.070.230.920.410.240.790.150.49-0.44-0.150.560.480.720.660.1
0.180.090.020.15-0.240.83-0.140.470.390.22-0.240.92-0.180.540.44-0.180.57-0.46-0.480.160.080.22
0.970.980.020.750.910.450.94-0.030.180.90.30.150.880.10.47-0.53-0.220.660.570.80.710.15
0.80.790.150.750.640.610.690.080.190.660.370.350.47-0.160.2-0.310.010.110.050.560.54-0.06
0.890.92-0.240.910.640.250.990.050.160.850.52-0.120.780.030.4-0.32-0.320.710.70.530.490.08
0.620.550.830.450.610.250.350.480.50.590.060.870.110.450.47-0.330.4-0.23-0.280.370.30.18
0.930.95-0.140.940.690.990.350.090.190.890.51-0.010.780.070.44-0.34-0.270.670.650.570.530.09
0.120.070.47-0.030.080.050.480.090.650.210.190.25-0.270.070.20.050.37-0.37-0.12-0.3-0.40.43
0.280.230.390.180.190.160.50.190.650.36-0.170.22-0.090.15-0.02-0.490.1-0.18-0.060.0-0.310.84
0.930.920.220.90.660.850.590.890.210.360.320.320.680.220.68-0.450.040.470.450.570.440.23
0.380.41-0.240.30.370.520.060.510.19-0.170.32-0.060.14-0.10.190.52-0.060.190.23-0.080.12-0.43
0.320.240.920.150.35-0.120.87-0.010.250.220.32-0.06-0.10.490.46-0.120.57-0.41-0.540.260.24-0.04
0.750.79-0.180.880.470.780.110.78-0.27-0.090.680.14-0.10.00.41-0.53-0.360.830.750.840.760.14
0.190.150.540.1-0.160.030.450.070.070.150.22-0.10.490.00.36-0.12-0.080.180.060.130.150.03
0.510.490.440.470.20.40.470.440.2-0.020.680.190.460.410.36-0.130.50.20.190.310.34-0.04
-0.45-0.44-0.18-0.53-0.31-0.32-0.33-0.340.05-0.49-0.450.52-0.12-0.53-0.12-0.130.15-0.36-0.28-0.64-0.32-0.67
-0.09-0.150.57-0.220.01-0.320.4-0.270.370.10.04-0.060.57-0.36-0.080.50.15-0.66-0.67-0.16-0.14-0.05
0.50.56-0.460.660.110.71-0.230.67-0.37-0.180.470.19-0.410.830.180.2-0.36-0.660.910.570.520.06
0.420.48-0.480.570.050.7-0.280.65-0.12-0.060.450.23-0.540.750.060.19-0.28-0.670.910.360.30.2
0.720.720.160.80.560.530.370.57-0.30.00.57-0.080.260.840.130.31-0.64-0.160.570.360.90.14
0.650.660.080.710.540.490.30.53-0.4-0.310.440.120.240.760.150.34-0.32-0.140.520.30.9-0.22
0.130.10.220.15-0.060.080.180.090.430.840.23-0.43-0.040.140.03-0.04-0.67-0.050.060.20.14-0.22
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, China Pharma Holdings has a Probability Of Bankruptcy of 60%. This is 38.6% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 50.64% lower than that of the firm.

China Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China Pharma could also be used in its relative valuation, which is a method of valuing China Pharma by comparing valuation metrics of similar companies.
China Pharma is currently under evaluation in probability of bankruptcy category among its peers.

China Pharma Main Bankruptcy Drivers

201920202021202220232024 (projected)
Return On Assets(0.24)(0.95)(0.15)(0.17)(0.57)(0.19)
Asset Turnover0.270.490.510.430.460.4
Gross Profit Margin0.140.180.0362(0.0609)(0.072)(0.0684)
Net Debt3.5M6.5M7.6M6.7M3.2M4.3M
Total Current Liabilities10.0M11.4M10.5M12.7M6.8M9.2M
Non Current Liabilities Total3.0M1.7M6.1M754.7K2.2M3.5M
Total Assets22.2M21.1M22.6M17.8M16.5M15.6M
Total Current Assets5.6M5.3M9.1M6.0M6.0M5.7M
Total Cash From Operating Activities608.3K(42.3K)(249.8K)(409.5K)(699.7K)(664.7K)

China Fundamentals

About China Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze China Pharma Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Pharma Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:
Check out China Pharma Piotroski F Score and China Pharma Altman Z Score analysis.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.69)
Revenue Per Share
0.63
Quarterly Revenue Growth
(0.16)
Return On Assets
(0.18)
Return On Equity
(0.75)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.